Molecular science company Caris Life Sciences said it filed a patent infringement suit against Foundation Medicine, Inc. in the US District Court for the District of Massachusetts Boston Division.
Caris said it is seeking damages and other relief for Foundation’s “willful infringement of Caris’ patent rights by its FoundationOne, FoundationACT and FoundationOne Heme products.”
“According to the complaint, Foundation Medicine infringes five US Patents held by Caris,” said Caris.
“The patents cover Caris’ novel system of performing molecular profiling of tumors to identify treatment options based on groups of molecular targets not traditionally or conventionally associated with various types of cancer.
“The system generates a molecular profiling report, which the treating physician may then use to develop a personalized treatment plan for the patient.”
Russ Farr, general counsel for Caris Life Sciences, said: “Before Caris’ tumor profiling invention, cancer treatment was based on a defined list of therapy options conventionally associated with a tumor’s tissue of origin.
“We have invested heavily in the development of our innovative technology for precision medicine because we strongly believe, and have demonstrated, that the molecular findings identified with tumor profiling can be utilized to provide cancer patients viable therapeutic options.
“We intend to vigorously defend our intellectual property and investment and take action against those who violate it.”
Caris Life Sciences is represented by Fish & Richardson in this case.